59 search results for CCL2
| # | SuperPathway Name | Genes Count | Relevance Score | |||||
|---|---|---|---|---|---|---|---|---|
| 1 | Blood-Brain Barrier and Immune Cell Transmigration: VCAM-1/CD106 Signaling | 104 | 1.200 | |||||
|
||||||||
| 2 | Development VEGF signaling via VEGFR2 - generic cascades | 147 | 0.430 | |||||
|
||||||||
| 3 | Non-genomic actions of 1,25 dihydroxyvitamin D3 | 51 | 0.430 | |||||
|
||||||||
| 4 | Akt Signaling | 682 | 0.430 | |||||
|
||||||||
| 5 | p53 transcriptional gene network | 95 | 0.430 | |||||
|
||||||||
| 6 | NF-kappaB Signaling | 327 | 0.430 | |||||
|
||||||||
| 7 | CCL18 signaling pathway | 96 | 0.430 | |||||
|
||||||||
| 8 | PAK Pathway | 686 | 0.430 | |||||
|
||||||||
| 9 | Nonalcoholic fatty liver disease | 46 | 0.430 | |||||
|
||||||||
| 10 | Interactions between immune cells and microRNAs in tumor microenvironment | 48 | 0.430 | |||||
|
||||||||
| 11 | A-beta Uptake and Degradation | 32 | 0.430 | |||||
|
||||||||
| 12 | MIF Mediated Glucocorticoid Regulation | 681 | 0.430 | |||||
|
||||||||
| 13 | Nuclear receptors meta-pathway | 315 | 0.430 | |||||
|
||||||||
| 14 | Cellular responses to stimuli | 802 | 0.430 | |||||
|
||||||||
| 15 | CCR5 Pathway in Macrophages | 321 | 0.430 | |||||
|
||||||||
| 16 | PERK regulates gene expression | 32 | 0.430 | |||||
|
||||||||
| 17 | Network map of SARS-CoV-2 signaling pathway | 48 | 0.430 | |||||
|
||||||||
| 18 | ERK Signaling | 1185 | 0.430 | |||||
|
||||||||
| 19 | AP-1 transcription factor network | 69 | 0.430 | |||||
|
||||||||
| 20 | p70S6K Signaling | 392 | 0.430 | |||||
|
||||||||
| 21 | Immune response IL-23 signaling pathway | 160 | 0.430 | |||||
|
||||||||
| 22 | Interleukin-6 family signaling | 33 | 0.430 | |||||
|
||||||||
| 23 | TGF-Beta Pathway | 653 | 0.430 | |||||
|
||||||||
| 24 | Angiogenesis (CST) | 89 | 0.430 | |||||
|
||||||||
| 25 | 17q12 copy number variation syndrome | 99 | 0.430 | |||||
|
||||||||
| 26 | Interactions of natural killer cells in pancreatic cancer | 27 | 0.430 | |||||
|
||||||||
| 27 | Lung fibrosis | 63 | 0.430 | |||||
|
||||||||
| 28 | IL-17 Family Signaling Pathways | 108 | 0.430 | |||||
|
||||||||
| 29 | Integrin Pathway | 570 | 0.430 | |||||
|
||||||||
| 30 | Ectoderm differentiation | 141 | 0.430 | |||||
|
||||||||
| 31 | Cytokine Signaling in Immune system | 732 | 0.430 | |||||
|
||||||||
| 32 | Immune infiltration in pancreatic cancer | 39 | 0.430 | |||||
|
||||||||
| 33 | CNTF Signaling | 149 | 0.430 | |||||
|
||||||||
| 34 | Vitamin B12 metabolism | 9 | 0.430 | |||||
|
||||||||
| 35 | Unfolded Protein Response (UPR) | 94 | 0.430 | |||||
|
||||||||
| 36 | Interleukin-4 and Interleukin-13 signaling | 108 | 0.430 | |||||
|
||||||||
| 37 | GPCR downstream signalling | 710 | 0.430 | |||||
|
||||||||
| 38 | Chemokine Superfamily: Human/Mouse Ligand-Receptor Interactions | 70 | 0.430 | |||||
|
||||||||
| 39 | Class A/1 (Rhodopsin-like receptors) | 556 | 0.430 | |||||
|
||||||||
| 40 | LDL Oxidation in Atherogenesis | 16 | 0.430 | |||||
|
||||||||
| 41 | IL3-mediated signaling events | 43 | 0.430 | |||||
|
||||||||
| 42 | Validated transcriptional targets of AP1 family members Fra1 and Fra2 | 35 | 0.430 | |||||
|
||||||||
| 43 | Glucocorticoid receptor pathway | 71 | 0.430 | |||||
|
||||||||
| 44 | Cell interactions of the pancreatic cancer microenvironment | 28 | 0.430 | |||||
|
||||||||
| 45 | MSP-RON Signaling | 48 | 0.430 | |||||
|
||||||||
| 46 | Antiviral and anti-inflammatory effects of Nrf2 on SARS-CoV-2 pathway | 32 | 0.430 | |||||
|
||||||||
| 47 | COVID-19 adverse outcome pathway | 10 | 0.430 | |||||
|
||||||||
| 48 | Spinal cord injury | 115 | 0.430 | |||||
|
||||||||
| 49 | Netrin-UNC5B signaling pathway | 52 | 0.430 | |||||
|
||||||||
| 50 | Burn wound healing | 75 | 0.430 | |||||
|
||||||||
| 51 | Signal Transduction | 2590 | 0.430 | |||||
|
||||||||
| 52 | SARS-CoV-2 innate immunity evasion and cell-specific immune response | 50 | 0.430 | |||||
|
||||||||
| 53 | Interleukin-10 signaling | 47 | 0.430 | |||||
|
||||||||
| 54 | Malignant pleural mesothelioma | 409 | 0.430 | |||||
|
||||||||
| 55 | Prostaglandin signaling | 28 | 0.430 | |||||
|
||||||||
| 56 | IL1 and megakaryocytes in obesity | 24 | 0.430 | |||||
|
||||||||
| 57 | Innate Immune System | 2025 | 0.430 | |||||
|
||||||||
| 58 | Fibrin complement receptor 3 signaling pathway | 43 | 0.430 | |||||
|
||||||||
| 59 | Folate metabolism | 11 | 0.430 | |||||
|
||||||||